Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03182140 · ClinicalTrials.gov registry record
KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 1,134
- Enrollment target
NCT03182140: Completed study, sponsored by Bayer.
NCT03182140 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 1,134 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03182140 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 1,134 participants
- Enrollment target
Study Summary
The main goal of this non-interventional study (NIS) is to evaluate user satisfaction with Kyleena in a real-life setting and to identify factors which influence user satisfaction, taking into account previously used contraceptive methods and reasons for use of Kyleena.
Primary Outcome
The rating is based on the 5-item Likert scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very dissatisfied).
Interventions
- DRUG Kyleena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,134 participants |
| Start Date | 2017-07-06 |
| Est. Completion | 2020-03-31 |
What the finished NCT03182140 record still lists
NCT03182140 is an observational study that tracks outcomes without assigning an intervention. Its 1,134 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Kyleena is the first listed.
NCT03182140 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03182140 about?
NCT03182140 is a clinical study titled "KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method". The main goal of this non-interventional study (NIS) is to evaluate user satisfaction with Kyleena in a real-life setting and to identify factors which influence user satisfaction, taking into account previously used contraceptive methods and reasons for use of Kyleena.
What is the current status of trial NCT03182140?
This trial is currently completed. The enrollment target is 1,134 participants. The study started on 2017-07-06. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT03182140?
The interventions under investigation include: Kyleena (DRUG).
Who is sponsoring clinical trial NCT03182140?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06445062 · 1,130 participants · Phase 1
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- NCT05894967 · 1,140 participants · NA
Moderators and Mediators of Perceptual Learning
- NCT06532487 · 1,140 participants · NA
Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities
- NCT06746129 · 1,126 participants · Phase 3
Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI